n n n ‘. concat(e. i18n. t(“search. voice. recognition_retry”),’n
The combination of real-time clinical knowledge bases and proprietary knowledge will enable venture capital firms to address portfolio building and expansion through knowledge-based insights and strengthened business partnerships.
PARIS, December 5, 2023–(BUSINESS WIRE)–Sofinnova Partners (“Sofinnova”), a leading European life sciences venture capital firm headquartered in Paris, London and Milan, announced the launch of Sofinnova. AI, a synthetic intelligence platform that seamlessly integrates complex computing functions with the company’s 50 years of industry experience, One of the world’s largest longitudinal, annotated and exclusive data sets on life sciences start-ups, enabling unprecedented insights into the discovery of life sciences innovation.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20231205517503/en/
Sofinnova. AI (Photo: Sofinnova)
Antoine Papiernik, President and Managing Partner of Sofinnova Partners, said: “Sofinnova. AI is pushing the traditional and artisanal technique to seek out and create investment opportunities, a process that until now has relied solely on our private networks and our meticulous technique. to attach disparate data over months or even years. By harnessing billions of insights spanning clinical literature, emerging healing spaces, and technological advancements, and merging them with all the proprietary wisdom accumulated over Sofinnova’s 50 years of experience, Sofinnova. AI will allow us to identify the next shots to the moon with unprecedented speed and accuracy. “
Sofinnova. AI is based on a structured and frequently updated database that tracks the global framework of human clinical knowledge in real time. The database contains:
> million authors of clinical publications
> million clinical publications
> 100,000 research institutes
> 4.5 million published patents
> 450,000 clinical trials
> 2 million and 1. 5 million founders
In addition to the structured knowledge base, Sofinnova. AI combines all proprietary data and specialized reviews accumulated through the corporation over time. A suite of proprietary knowledge research teams, adding a custom LLM (large language model), a build for ChatGPT allows Sofinnova groups to question this large knowledge base in the most effective way possible. This equipment will enable the company to identify hidden poles of life sciences research, anticipate emerging clinical trends, and connect with the next generation of innovators, among other uses. Cases.
Papiernik concluded, “Our committed team of knowledge scientists and AI experts have spent the last four years meticulously creating Sofinnova. AI. This will allow us to assess opportunities from a much broader perspective, allowing us to look beyond the horizon into the long term. . in the most effective way, so we can spend more time focusing on people. Sofinnova. AI will decorate our investment methods by allowing us to spend more time harnessing our collective human intelligence to strengthen relationships with our entrepreneurs. This will allow us to remain at the forefront of innovation to fund those who are in fact shaping the future of life sciences.
About Sofinnova Partners
Sofinnova Partners is a leading European life sciences venture capital corporation focused on healthcare and sustainability. Headquartered in Paris, London and Milan, the corporation brings together a team of professionals from all over the world with strong scientific, medical and advertising backgrounds. Sofinnova Partners is a corporate founder active across the life sciences investment value chain, from seed to overdue. The company actively partners with ambitious marketers as a lead investor or leader to develop transformative inventions that have the potential to have a definite impact on our collective. future.
Founded in 1972, Sofinnova Partners is a venture capital firm with deep roots in Europe, with 50 years of experience supporting more than 500 corporations and construction market leaders worldwide. Today, Sofinnova Partners manages more than €2. 5 billion. For more information, please visit: sofinnovapartners. com.
See the businesswire. com edition: https://www. businesswire. com/news/home/20231205517503/en/
Contacts
Bommy Lee Head of CommunicationsSofinnova [email protected] +33 (0) 6 47 71 38 11
North America RooneyPartners LLCKate Barrettekbarrette@rooneypartners. com 1 212 223 0561
UK Optimum Strategic CommunicationsHana Maliksofinnova@optimumcomms. com 44 (0) 20 3922 0900